These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22096611)

  • 1. Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety.
    Segarra TJ; Fakioglu E; Cheshenko N; Wilson SS; Mesquita PM; Doncel GF; Herold BC
    PLoS One; 2011; 6(11):e27675. PubMed ID: 22096611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
    Wilson SS; Cheshenko N; Fakioglu E; Mesquita PM; Keller MJ; Herold BC
    Antivir Ther; 2009; 14(8):1113-24. PubMed ID: 20032541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.
    Galen BT; Martin AP; Hazrati E; Garin A; Guzman E; Wilson SS; Porter DD; Lira SA; Keller MJ; Herold BC
    J Infect Dis; 2007 May; 195(9):1332-9. PubMed ID: 17397004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
    Shankar GN; Alt C
    J Antimicrob Chemother; 2014 Dec; 69(12):3282-93. PubMed ID: 25139839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model.
    Bourne N; Bernstein DI; Ireland J; Sonderfan AJ; Profy AT; Stanberry LR
    J Infect Dis; 1999 Jul; 180(1):203-5. PubMed ID: 10353881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials.
    Abdool Karim SS
    Future Microbiol; 2010 Apr; 5(4):527-9. PubMed ID: 20353292
    [No Abstract]   [Full Text] [Related]  

  • 7. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
    Seay K; Khajoueinejad N; Zheng JH; Kiser P; Ochsenbauer C; Kappes JC; Herold B; Goldstein H
    J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
    Nixon B; Jandl T; Teller RS; Taneva E; Wang Y; Nagaraja U; Kiser PF; Herold BC
    Antimicrob Agents Chemother; 2014; 58(2):1153-60. PubMed ID: 24323471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge.
    Hsu M; Aravantinou M; Menon R; Seidor S; Goldman D; Kenney J; Derby N; Gettie A; Blanchard J; Piatak M; Lifson JD; Fernández-Romero JA; Zydowsky TM; Robbiani M
    AIDS Res Hum Retroviruses; 2014 Feb; 30(2):174-83. PubMed ID: 24117013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.
    Mayer KH; Karim SA; Kelly C; Maslankowski L; Rees H; Profy AT; Day J; Welch J; Rosenberg Z;
    AIDS; 2003 Feb; 17(3):321-9. PubMed ID: 12556685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission.
    Cone RA; Hoen T; Wong X; Abusuwwa R; Anderson DJ; Moench TR
    BMC Infect Dis; 2006 Jun; 6():90. PubMed ID: 16740164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use.
    Kenney J; Singer R; Derby N; Aravantinou M; Abraham CJ; Menon R; Seidor S; Zhang S; Gettie A; Blanchard J; Piatak M; Lifson JD; Fernández-Romero JA; Zydowsky TM; Robbiani M
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1476-84. PubMed ID: 22737981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.
    O'Loughlin J; Millwood IY; McDonald HM; Price CF; Kaldor JM; Paull JR
    Sex Transm Dis; 2010 Feb; 37(2):100-4. PubMed ID: 19823111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.
    Marrazzo JM; Rabe L; Kelly C; Richardson B; Deal C; Schwartz JL; Chirenje ZM; Piper J; Morrow RA; Hendrix CW; Marzinke MA; Hillier SL;
    J Infect Dis; 2019 May; 219(12):1940-1947. PubMed ID: 30753642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse.
    Moench TR; Mumper RJ; Hoen TE; Sun M; Cone RA
    BMC Infect Dis; 2010 Nov; 10():331. PubMed ID: 21087496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.
    Malonza IM; Mirembe F; Nakabiito C; Odusoga LO; Osinupebi OA; Hazari K; Chitlange S; Ali MM; Callahan M; Van Damme L
    AIDS; 2005 Dec; 19(18):2157-63. PubMed ID: 16284466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial.
    Lacey CJ; Woodhall S; Qi Z; Sawant S; Cowen M; McCormack S; Jiang S
    Int J STD AIDS; 2010 Oct; 21(10):714-7. PubMed ID: 21139151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
    Keller MJ; Zerhouni-Layachi B; Cheshenko N; John M; Hogarty K; Kasowitz A; Goldberg CL; Wallenstein S; Profy AT; Klotman ME; Herold BC
    J Infect Dis; 2006 Jan; 193(1):27-35. PubMed ID: 16323128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand.
    Whitehead SJ; McLean C; Chaikummao S; Braunstein S; Utaivoravit W; van de Wijgert JH; Mock PA; Siraprapasiri T; Friedland BA; Kilmarx PH; Markowitz LE
    PLoS One; 2011; 6(9):e14831. PubMed ID: 21915249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.